{"groups":[{"description":"Ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15; lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15, and 22 of a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity (up to 20 cycles)","id":"FG000","title":"Ixazomib+Lenalidomide+Dexamethasone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"22"}],"type":"Participants Ongoing on Study Treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"12"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Unsatisfactory Therapeutic Response"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrawal by Participant"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Reason not Defined"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"43"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"43"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Asian participants with a diagnosis of relapsed and/or refractory multiple myeloma were enrolled and received a combination of ixazomib, lenalidomide and dexamethasone.","recruitmentDetails":"Participants took part in the study at 8 investigative sites in Singapore, Hong Kong and South Korea from 17 December 2012 to 11 April 2017. Data cut-off for the analysis was 14 July 2014."}